Alexza Pharmaceuticals Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statement of Cash Flows

In millions of USD, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Net loss
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense
Change in fair value of contingent consideration liability
Recognition of right to borrow asset
Amortization of debt discount and deferred interest
Amortization of discount on available-for-sale securities
(Gain)/loss on disposal of property and equipment
Depreciation and amortization
Loss/(gain) on disposal of property and equipment
Impairment of property and equipment
Impairment of inventory
Impairment of prepaid expenses

Changes in operating assets and liabilities:
Receivables
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued clinical trial expense and other accrued liabilities
Deferred revenues
Other liabilities
Net cash used in operating activities
Net cash used in operating activities
Cash flows from investing activities:
Purchase of available-for-sale securities
Maturities of available-for-sale securities
Purchases of property and equipment
Proceeds from disposal of property and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Proceeds from issuance of common stock, common stock warrants and exercise of stock options and stock purchase rights
Payment of contingent payment to Symphony Allegro Holdings, LLC
Change in restricted cash
Proceeds from financing obligations
Payments of financing obligations
Net cash provided by financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of cash flow information
Cash paid for interest
Non cash investing and financing activities:
Debt discount related to Teva Note
Reversal of Note Payable to Autoliv
Value of warrants issued with royalty securitization financing
Value of the beneficial conversion feature related to borrowing against Teva Note
Value of right to borrow asset reclassified as debt discount

Comments